The addition of HCC surveillance with the standard recommendation for biannual ultrasound and AFP would be cost-effective if the HCC risk is ≥ 0.55% per year such as patients with cirrhosis who have an estimated HCC incidence of over 3%/yr. This evidence concerns the gene AFP and hepatocellular carcinoma.